Company news
Faron Pharmaceuticals Oy (LSE:FARN) news
Faron Pharmaceuticals Oy news releases on 6ix. Latest, Aug 30, 2024: Grant of options
Press releases — page 4
Grant of options
August 30, 2024
FDA Grants Fast Track Designation for Bexmarilimab
August 27, 2024
Faron 2024 Half-Year Financial Results
August 27, 2024
Notice of Half-Year Financial Results
August 20, 2024
Traumakine Research Collaboration and DoD Grant
August 13, 2024
Appointment of Chief Financial Officer
August 8, 2024
Faron Appoints Dr. Petri Bono as new CMO
August 6, 2024
Faron Announces Positive FDA Feedback
July 11, 2024
Update on settlement
June 25, 2024
Holding(s) in Company - Replacement
June 25, 2024
New shares registered with Finnish Trade Register
June 20, 2024
Fully subscribed EUR 30.7 million share offering
June 20, 2024
Proposed REX Retail Offer
June 5, 2024
Faron commences a share offering
June 4, 2024
Initial positive data from Phase 2 of BEXMAB
May 20, 2024
Issuance of warrants
May 17, 2024
Founders named European Inventor Award finalists
May 16, 2024
Replacement – Board Change
May 13, 2024
Update on financial status
April 30, 2024
Board Change
April 30, 2024
Faron confirms plans under new leadership
April 16, 2024
Approval of Warrant Terms and Conditions
April 8, 2024
Decisions of the Board of Directors
April 8, 2024
Appointment of Chief Executive Officer
April 8, 2024
Results of the Annual General Meeting
April 5, 2024
Announcement of Placing
April 4, 2024
Issue of Warrants to IPF Funding Update
March 28, 2024
Faron´s Annual Report 2023
March 26, 2024
Additional Positive Data from Phase 1 of BEXMAB
March 18, 2024
Faron to Host BEXMAB Webcast
March 14, 2024
Notice of Annual General Meeting 2024
March 13, 2024
Financial Statement January 1 to December 31 2023
March 13, 2024
Binding commitments for convertible loans
March 4, 2024
Replacement - Update to 2024 Financial Calendar
February 28, 2024
Update to Faron’s Financial Calendar for 2024
February 27, 2024
Continued Negotiations Regarding Events of Default
February 21, 2024
Events of Default
February 19, 2024
Further re: Exercise of options
January 31, 2024
BEXMAB Insights into Patient Profiles
January 25, 2024
Exercise of options - Issue of equity
January 19, 2024
First Patient Dosed in Ph 2 of the BEXMAB Trial
January 9, 2024
Presentation at J.P. Morgan Healthcare Conference
January 3, 2024
Faron’s Financial Calendar for 2024
December 22, 2023
Phase 1 BEXMAB data presented at ASH
December 11, 2023
MATINS Trial in Cell Reports Medicine
December 7, 2023
Faron Initiates Phase 2 Part of BEXMAB Study
November 6, 2023
Faron to present data from BEXMAB study at ASH
November 2, 2023
Manager's transactions
October 27, 2023
Exercise of options
October 27, 2023
Results of Placing
October 27, 2023